Skip to main content
. 2022 Aug 25;14:888784. doi: 10.3389/fnagi.2022.888784

FIGURE 3.

FIGURE 3

LEV treatment promotes the clearance of Aβ in KA-stimulated APP23/MAPT mice. (A,B) Protein levels of Beclin1, LC3, APOE, LRP1, RAGE, IDE, and NEP in the brains of KA (10 mg/kg/d)- or LEV (50, 100, 150, or 200 mg/kg/d) + KA-treated APP23/MAPT mice. (C) Mouse neuroblastoma cell line N2a cells are treated with hAβ (10 ng/mL) for 24 h; after incubation with KA and LEV (50, 100, 150, or 200 M), the remaining hAβ-treated cells were assessed using enzyme-linked immunosorbent assay and the survival rate was calculated using the MTT assay. (D) hAβ (3 μg) was intracerebroventricularly injected into the mice; after 24 h, the levels of hAβ in the brain and plasma of APP23/MAPT mice were determined using enzyme-linked immunosorbent assay (*P < 0.05; **P < 0.01; ***P < 0.001 vs. the control group; #P < 0.05; ##P < 0.01; ###P < 0.001 vs. the KA-treated group, Student’s t-test). KA, kainic acid; LEV, levetiracetam; Aβ, amyloid β-peptide; h, human.